Induction and Maintenance Agents
Immunosuppression has increased the success of human heart transplant. There are specific patient groups that benefit from the use of induction therapy though the use of induction therapy has not shown universal benefit for all patients. Currently heart transplant centers employ dual or triple immunosuppression regimens with a calcineurin inhibitor as the base of the regimen and consideration given to antiproliferative agents or PSI/mTOR as the additional agent, with or without corticosteroids. The tolerability of agents can limit their use despite the therapeutic benefit, in addition to immunosuppression, toward renal sparing effects, viral sparing effects, or vasculopathy benefits. The choice of agents make individualization of immunosuppression possible based on a specific patient’s needs.
KeywordsMaintenance immunosuppression Heart transplant induction PSI/mTOR antiviral properties PSI/mTOR CAV C2 monitoring Calcineurin inhibitors Antiproliferative agents
- Cantarovich M, Besner HG, Barkun JS et al (1998) Two-hour cyclosporine level determination is the appropriate tool to monitor neoral therapy. Clin Transpl 12(3):243–249Google Scholar
- Salgo R, Grossman J, Schofer H et al (2010) Switch to sirolimus based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 10:1395–1393CrossRefGoogle Scholar
- van Gelder T, Klupp J, Barten MJ et al (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23(2):19–128Google Scholar